Alopecia News

ORLANDO — In this Healio video exclusive, Jeanine Downie, MD, FAAD, discussed the Unplugged session from the American Society for Dermatologic Surgery Annual Meeting.

Low-dose oral minoxidil was not significantly associated with pericardial effusion among patients with alopecia, according to a study.

Leqselvi demonstrated clinically meaningful improvements long-term in adults with alopecia areata, Sun Pharma announced in a press release.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

A newly published study found that an alopecia diagnosis precedes additional psychiatric and autoimmune diagnoses in affected patients.

The FDA’s inaction approving sunscreen ingredients as well as studies about endocrine-disrupting chemicals in personal care products and Ozempic’s impact on hidradenitis suppurativa led Healio Dermatology’s most-read articles in September.

A phase 2b study of rezpegaldesleukin for treating alopecia areata is underway following the drug’s success in other autoimmune diseases, according to a poster presented at the European Academy of Dermatology and Venerology Congress.

A twice-daily dose of oral deuruxolitinib showed better alopecia areata results compared with a once-daily dose, according to a poster presented at the European Academy of Dermatology and Venereology Congress.